

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043991 A3

(51) International Patent Classification⁷: C12Q 1/56

(21) International Application Number:
PCT/US2003/035608

(22) International Filing Date:
6 November 2003 (06.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/425,662 13 November 2002 (13.11.2002) US
60/466,214 28 April 2003 (28.04.2003) US

(71) Applicant (for all designated States except US): HAEMATOLOGIC TECHNOLOGIES, INC. [US/US]; 27 River Road, Unit 1021, Essex Junction, VT 05452 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JENNY, Richard, J. [US/US]; 31 Brigham Hill Lane, Essex Junction, VT 05452 (US). BUTENAS, Saulius [LT/US]; 76 Oakwood Drive, South Burlington, VT 05403 (US).

(74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
15 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR TISSUE FACTOR AND FACTOR VIIA

(57) **Abstract:** The invention provides assays for detecting and quantitating tissue factor and factor VIIa in simple and complex biological systems. The assays are performed by detecting and/or measuring the tissue factor cofactor activity and factor VIIa enzymatic activity using aminonaphthalene-based fluorogenic substrates.

Assay for Tissue Factor and Factor VIIa

This application claims priority from U.S. Provisional Application 60/425662, filed November 6, 2002, and U.S. Provisional Application 60/466214, filed April 28, 2003, each of which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION1. Field of the Invention

The invention relates, generally, to the field of detection of proteins involved in blood coagulation. More specifically, it relates to a method for determining the amount of tissue factor and/or factor VIIa in simple and complex biological systems.

2. Description of the Related Art

Tissue factor (TF) and factor VIIa (fVIIa) are essential components for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating fVIIa.

Although several assays for fVIIa have been described (some commercially available), those assays do not discriminate between factor VII and factor VIIa, either due to the lack of specificity in immunologic methods, or due to the feedback-activation of factor VII in the amidolytic and clot-based assays. For example, there is a "direct" factor VIIa assay based upon clotting of plasma initiated with a soluble mutant of TF. The assay involves the entire coagulation cascade, so it is therefore sensitive to the concentration of procoagulant proteins and coagulation inhibitors as well as factor VII by virtue of feed-back activation. Thus, the clotting time of plasma reflects the concentration of fVIIa, as well as, the concentration of all components of plasma involved in coagulation and its regulation.

Moreover, because of the critical role TF plays in hemostasis, its potential role in metastasis, and its extensive use in-vitro, it is important to have a sensitive and specific TF

assay that can detect relatively low amounts of this protein in biological fluids, cell cultures, lysates, and in purified and semi-purified systems. TF assays thus far developed employ clotting, chromogenic, and immunochemical methods. The
5 clotting methods involve the entire coagulation cascade and are therefore sensitive to alterations in the levels of procoagulant proteins and coagulation inhibitors. Chromogenic methods do not allow a direct measure of TF activity, and are expensive since they require additional purified coagulation
10 factors. Similarly, immunochemical methods are relatively expensive and time-consuming. Thus, at the present time, there is no quick, accurate and somewhat universal method to directly measure TF activity.

15 Accordingly, a functional-based assay that could be used to measure TF or fVIIa in purified and/or complex biological systems would have a variety of potential applications. These include: in-vitro diagnostics for the assessment of hemostatic potential; in-vitro diagnostics for thrombotic risk assessment;
20 in-vitro diagnostics for cancer screening; quality control during the purification of recombinant tissue factor; quality control during the manufacture of prothrombin time PT reagents; and characterization of final TF and/or PT reagents.

25 It has been demonstrated that the amidolytic activity of the TF/factor VIIa complex toward small fluorogenic substrates is membrane (phospholipid) independent. This suggests that TF can be successfully quantitated in a free form in purified systems and biological fluids, as well as, present on cell or
30 artificial membranes and in cell lysates. Fluorogenic substrates, which allow a quantitation of low concentrations of factor VIIa (as described above), will similarly allow the quantitation of low concentrations of TF. U.S. Patent No. 5,399,487, which is fully incorporated by reference, discloses
35 fluorogenic substrates for serine proteases that contain 6-amino-1-naphthalenesulfonamide (ANSN) leaving groups.

SUMMARY OF INVENTION

The invention provides assays for detecting and quantitating tissue factor and factor VIIa in purified form or in complex biological mixtures such as body fluids and tissues, e.g., plasma. The assay is performed by detecting and/or measuring the TF-dependent fVIIa enzymatic activity using aminonaphthalene sulfonamide-based (ANSN-based) fluorogenic substrates. The TF-dependent activity is an important aspect of this assay, as the TF/factor VIIa complex will yield nearly a 100-fold higher rate of substrate hydrolysis relative to factor VIIa alone with appropriate substrates. It has been demonstrated that the properties of the ANSN-based fluorogenic substrates allow for the direct quantitation of fVIIa at low (<5) picomolar concentrations in purified systems.

The enzymatic activity of a TF/fVIIa complex is related to the concentration of either TF or fVIIa in the sample, depending upon which is present at a limiting concentration. Standard calibration curves can be generated using samples with known concentrations of TF or fVIIa. The concentration of active TF or fVIIa in a sample suspected of containing these factors can be determined by comparing the detected enzymatic activity to the calibration curves.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a fluorogenic assay calibration curve for factor VIIa amidolytic activity in the presence of excess (5nM) TF;

FIG. 2 is a fluorogenic assay calibration curve for TF cofactor activity in the presence of excess (2 nM) factor VIIa; and

FIG. 3 is a calibration curve for TF activity where TF activity is expressed as the amount of cofactor activity per milliliter of solution (units/ml). RFU represents relative fluorescent units.


DETAILED DESCRIPTION OF THE INVENTION

As noted above, the invention provides assays for tissue factor and factor VIIa. There are two broad aspects of the invention.

5 One aspect is a method used to determine the cofactor activity of TF in a fluid sample suspected of containing TF or containing an unknown quantity of TF. The term "determine" as used herein encompasses both quantitative measurements as well
10 as qualitative assessments. Thus, the methods of the invention can be used to determine (1) if any TF is present in a sample and (2) the amount of TF activity in a sample. In the first aspect, the assay initially involves combining the sample suspected to contain TF with fVIIa to form a TF/fVIIa complex,
15 i.e., a reaction mixture. Optionally, added to the reaction mixture are divalent metal ions, such as calcium ion, or metal ion chelators, such as ethylenediaminetetraacetic acid (EDTA) and ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA). Other optional components of the
20 reaction mixture include alcohols and polyhydroxylated materials. Representative alcohols include lower alcohols, e.g., C₁-C₆ alcohols such as methanol, ethanol, propanol, pentanol, and hexanol. Polyhydroxylated materials include various glycols and sugars. Representative polyhydroxylated
25 materials include glycerol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, trimethylene glycol, butylene glycols, 1,2-cyclohexanediol, poly(oxyalkylene)polyols derived from the condensation of ethylene oxide, propylene oxide, or any combination thereof,
30 1,1,1-trimethylolpropane, 1,1,1-trimethylolethane, 2,2-dimethyl-1,3-propane diol, and pentaerythritol. More preferably, the alcohol is ethanol or n-propanol. Preferred polyhydroxylated materials include glycerol, ethylene glycol, and propylene glycol. More preferably, the polyhydroxylated
35 material is ethylene glycol or propylene glycol.

Typically, the TF sample is combined with a molar excess of fVIIa to produce a TF/fVIIa enzyme complex in a TF limiting manner. When developing a calibration curve, there is a possibility that fVIIa may not be present in an excess relative to the concentration of TF. If so, there will be no change in the fluorescence level with change in concentration, i.e., a flat line will be generated, until the TF concentration is reduced to a point where fVIIa is in excess. Preferably, the excess of fVIIa is about a 2-fold excess. Alternatively, the molar excess of fVIIa is about a 100-fold molar excess; in yet another alternative, the excess of fVIIa is about a 1000-fold excess. Finally, the enzymatic activity of the complex may be detected, preferably by using an amino-naphthalenesulfonamide-based fluorogenic substrate. Fluorescence can be monitored (continuously or discontinuously) using a suitable fluorescence spectrophotometer. Representative devices include (a) Perkin Elmer model MPF-44A; (b) a Perkin Elmer Model LS50B; (c) a Molecular Devices Spectramax fluorescence plate reader. When an ANSN-based fluorescent substrate is used, the fluorophore is preferably detected using monochrometers set at an excitation wavelength of about 340-360 nm, preferably about 350 nm, and an emission wavelength of about 460-480 nm, preferably about 470 nm. Light scattering artifacts can be minimized using an appropriate cut-off filter in the emission light beam, e.g., a 435 nm cut off filter.

The amino-naphthalenesulfonamide (ANSN) based fluorogenic substrate used is a compound of the formula:



or a pharmaceutically acceptable non-toxic salts thereof; wherein

R₁ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms optionally substituted with

C₁-C₆ alkoxy, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, cycloalkylalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula



R₅ represents hydrogen or an amino acid side chain;
and

R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or a peptide residue;

R₂ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula



R₅ represents hydrogen or an amino acid side chain;
and

R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or peptide residue; or

NR₁R₂ forms a nitrogen heterocycle; and

R₃ is an amino acid or a peptide residue.

These substrates can be prepared as described in U.S. Patent No. 5,399,437. Suitable substrates include the following: D-FPR-(cyclohexyl)ANSN (where FPR represents Phe-Pro-Arg, ANSN represents aminonaphthalenesulfonamide, R₁ is cyclohexyl and R₂ is hydrogen); D-FPR-(ethyl)ANSN (R₁ is ethyl and R₂ is hydrogen), D-FPR-(n-propyl)ANSN (R₁ is n-propyl and R₂ is hydrogen), D-FPR-(n-butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), D-FPR-(n-hexyl)ANSN (R₁ is n-hexyl and R₂ is hydrogen), D-FPR-(benzyl)ANSN (R₁ is benzyl and R₂ is hydrogen), D-FPR-(hexamethylene)ANSN (NR₁R₂ represents an azepan-1-yl group), D-FPR-(isopropyl)ANSN (R₁ is isopropyl and R₂ is hydrogen), D-FPR-(methoxyethylene)ANSN (R₁ is methoxyethyl and R₂ is hydrogen), D-FPR-(t-butyl)ANSN (R₁ is t-butyl and R₂ is hydrogen), D-FPR-(methylacetate)ANSN (R₁ is -CH₂CO₂CH₃ and R₂ is hydrogen), D-FPR-(di-ethyl)ANSN (R₁ and R₂ are both ethyl), Boc-D-FPR-(cyclohexyl)ANSN (R₁ is cyclohexyl and R₂ is hydrogen), (p-F)FPR-(ethyl)ANSN (R₁ is ethyl and R₂ is hydrogen), Boc(p-F)FPR-(ethyl)ANSN (R₁ is ethyl and R₂ is hydrogen), D-FVR-(ethyl)ANSN (R₁ is ethyl and R₂ is hydrogen), Boc-D-FVR-(ethyl)ANSN (R₁ is ethyl and R₂ is hydrogen), D-LPR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), Boc-D-LPR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), D-VPR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), Boc-D-VPR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), L-VPR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), Boc-L-VPR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), D-VLR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), Boc-D-VLR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), L-VLR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), Boc-L-VLR-(butyl)ANSN (R₁ is n-butyl and R₂ is hydrogen), D-LSR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), Boc-D-LSR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), D-FLR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), Boc-D-FLR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), L-FLR-(propyl)ANSN (R₁ is propyl and R₂ is hydrogen), D-VSR-(isopropyl)ANSN (R₁ is isopropyl and R₂ is hydrogen), Boc-D-

VSR-(isopropyl)ANSN (R_1 is isopropyl and R_2 is hydrogen), D-LGR-(cyclohexyl)ANSN (R_1 is cyclohexyl and R_2 is hydrogen), Boc-D-LGR-(cyclohexyl)ANSN (R_1 is cyclohexyl and R_2 is hydrogen), D-PFR-(isopropyl)ANSN (R_1 is isopropyl and R_2 is hydrogen), and Mes-D-LGR(di-ethyl)ANSN (R_1 and R_2 are both ethyl). A preferred substrate is D-FPR-(cyclohexyl)ANSN.

In addition to fluorogenic substrates, chromogenic substrates such as p-nitroaniline-based (pNA-based) substrates may be employed.

10

Tissue factor from a variety of sources and species can be assayed using the invention. Preferably, the TF to be assayed with the invention is human TF. There are several sources for human TF. The sources include brain tissue, placenta, endothelial cells, tissue extract, plasma, cell extract, synthetic or naturally derived thromboplastin, and recombinant human TF. The fVIIa used in the TF assay is preferably either native human factor VIIa or recombinant factor VIIa, although factor VIIa from other species and sources may be employed.

20

The concentration of TF in the sample can be determined by quantifying the TF-dependent enzymatic activity of the TF/fVIIa complex. This involves comparing the TF-dependent enzymatic activity to a standard calibration curve. Quantifying the TF-dependent enzymatic activity of the TF/fVIIa complex in a sample with known concentrations of TF generates the standard curve. The concentrations of TF used for creating the standard curve may range from about 0.1 pM to about 1mM, as long as factor VIIa is maintained in a molar concentration greater than that of TF, i.e., in excess relative to the TF molar concentration.

30

The specificity, sensitivity and limits of detection of the tissue factor assay may be modulated by employing techniques to physically capture tissue factor from the sample solution.

35

This may be accomplished by, for example, using immunocapture techniques that employ immobilized anti-tissue factor antibodies or by immobilizing the enzyme (factor VIIa) itself.

Using such techniques, tissue factor can be captured or
5 removed from solution while extraneous materials are washed away. Techniques suitable for adhering antibodies to assay plates are well-known in the art as are methods for immobilizing enzymes such as fVIIa. Suitable anti-tissue factor antibodies are commercially available or may be prepared using
10 methods known in the art.

The performance of the tissue factor assay can be enhanced if desired by adjusting various assay conditions. For example, the pH and ionic strength of the assay buffer can be adjusted.
15

The second aspect of the invention is a method used to determine the fVIIa enzymatic activity in a sample, preferably a fluid sample, suspected of containing fVIIa or containing an
20 unknown quantity of fVIIa.

As noted above, the term "determine" as used herein encompasses both quantitative measurements as well as qualitative assessments. Thus, the methods of the invention can be used to
25 determine (1) if any fVIIa is present in a sample and (2) the amount of fVIIa activity in a sample.

The assay in the second aspect first involves combining TF and fVIIa to form a TF/fVIIa complex, i.e., a reaction mixture.
30 Optionally, added to the reaction mixture are divalent metal ions, such as calcium ion, or metal ion chelators, such as ethylenediaminetetraacetic acid (EDTA) and ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA). Other optional components of the reaction mixture include
35 alcohols and polyhydroxylated materials. Representative alcohols include lower alcohols, e.g., C₁-C₆ alcohols such as

methanol, ethanol, propanol, pentanol, and hexanol. Polyhydroxylated materials include various glycols and sugars.

Representative polyhydroxylated materials include glycerol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, trimethylene glycol, butylene glycols, 1,2-cyclohexanediol, poly(oxyalkylene)polyols derived from the condensation of ethylene oxide, propylene oxide, or any combination thereof, 1,1,1-trimethylolpropane, 1,1,1-trimethylolethane, 2,2-dimethyl-1,3-propane diol, and pentaerythritol. More preferably, the alcohol is ethanol or n-propanol. Preferred polyhydroxylated materials include glycerol, ethylene glycol, and propylene glycol. More preferably, the polyhydroxylated material is ethylene glycol or propylene glycol.

Factor VIIa from a variety of sources and species can be assayed using the methods of the invention. Preferably, the fVIIa to be assayed is human factor VIIa. Possible sources include plasma, tissue extract, cell extract or recombinant material. Preferably, the TF used in the fVIIa assay is native human tissue factor or recombinant human tissue factor, although TF from other sources may be employed. Possible sources of TF also include synthetic or naturally derived thromboplastin.

The concentration of fVIIa in the sample can be found by quantifying the fVIIa-dependent enzymatic activity of the TF/fVIIa complex. This involves comparing the fVIIa dependent enzymatic activity to a standard calibration curve. Quantifying the fVIIa-dependent enzymatic activity of the TF/fVIIa complex in a sample with known concentrations of fVIIa generates the standard curve. The concentrations of fVIIa used for creating the standard curve may range from about 0.1 pM to about 1mM, so long as TF is maintained in a molar excess over the factor VIIa.

When developing a calibration curve, there is a possibility that TF may not be present in an excess relative to the concentration of fVIIa. If so, there will be no change in the fluorescence level with change in concentration, i.e., a flat line will be generated, until the fVIIa concentration is reduced to a point where TF is in excess. Preferably, the excess of TF is about a 2-fold excess; alternatively, the molar excess of TF is about a 100-fold molar excess; in another alternative, the excess of TF is about a 1000-fold excess.

10

Enzymatic activity of the complex may be determined in a manner similar to that used to assay for TF.

The specificity, sensitivity and limits of detection of the basic factor VIIa assay described above may be enhanced by employing techniques to physically capture factor VIIa from the sample solution. This may be accomplished using immunocapture techniques that employ immobilized anti-factor VIIa antibodies or by immobilizing the cofactor (tissue factor) itself. In this manner, factor VIIa may be captured from solution while extraneous materials are washed away in subsequent steps

The performance of the factor VIIa assay can be enhanced if desired by adjusting various assay conditions. As with the TF assay, for example, the pH and ionic strength of the assay buffer can be adjusted.

This invention is illustrated further by the following examples, which are not to be construed as limiting the invention in scope or spirit to the specific compounds or procedures described in them.

EXAMPLE 1

Varying concentrations of fVIIa (0-1000 pM) were incubated with 5 nM TF in 20 mM Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 0.15 M Sodium Chloride (NaCl), pH 7.4 (HBS), containing 20 mM EDTA for 10 minutes at room

temperature, followed by the addition of 100 μM D-FPR-(cyclohexyl)ANSN. Substrate hydrolysis was monitored continuously for five minutes in a fluorometer at an excitation wavelength of 350 nm and an emission wavelength of 470 nm. The rates of substrate hydrolysis were determined for each fVIIa concentration tested. FIG. 1 is a graph of a calibration line based on these rates of hydrolysis at various factor VIIa concentrations. FIG. 1 shows that the factor VIIa/TF dependent rate of substrate hydrolysis is linear over the range of factor VIIa concentrations tested.

EXAMPLE 2

Normal citrated plasma was diluted (1:1) with HBS containing 20 mM EDTA, and the pH was adjusted to 7.4. Five nM TF was then added. The plasma was incubated for 10 minutes at room temperature followed by the addition of 100 μM D-FPR-(cyclohexyl)ANSN. The rates of substrate hydrolysis were determined. In a control experiment, the rate of substrate hydrolysis was evaluated for the same plasma sample, but in the absence of TF. The increased rate of substrate hydrolysis observed in the presence of TF (versus the control) was attributed to the activity of the factor VIIa/TF complex. The results were compared to the FIG. 1 calibration curve. The plasma sample yielded a fVIIa concentration of 102 pM.

EXAMPLE 3

Concentrations of TF were varied (0-500 pM) and incubated with 2 nM fVIIa in HBS pH 7.4, containing 2 mM Calcium Chloride (CaCl_2), for 10 minutes at room temperature. Next, 50 μM D-FPR-(n-butyl)ANSN was added. Substrate hydrolysis was then monitored continuously for five minutes in a fluorometer at an excitation wavelength of 350 nm and an emission wavelength of 470 nm. The rates of substrate hydrolysis were determined for each TF concentration tested. The rate of hydrolysis by 2 nM fVIIa alone was measured and subtracted from the rates observed in the presence of TF. FIG. 2 is a graph of a calibration line based on these rates of hydrolysis at various TF

concentrations. FIG. 2 shows that the factor VIIa/TF dependent rate of substrate hydrolysis is linear over the range of TF concentrations tested.

EXAMPLE 4

5 In this example the preparation for TF employed in Example 3 was relipidated into phospholipid (PCPS) vesicles, composed of 75% phosphatidylcholine (PC) and 25% phosphatidylserine (PS). Relipidated TF, 250pM TF to 500 nM PCPS, was incubated with 2 nM fVIIa in HBS, 2mM CaCl₂ pH 7.4 for ten minutes at room
10 temperature. Next, 50 μ M D-FPR-(n-butyl)ANSN was added. Rates of hydrolysis were determined and the rate of hydrolysis by 2 nM fVIIa alone was measured and subtracted from the rates observed in the presence of TF. The net rate of hydrolysis was then compared to the FIG. 2 calibration curve. The assay data
15 indicates that 35-40% of the TF added to the relipidation mixture was expressed as functional TF, which indicates poor recovery of total TF activity following relipidation.

EXAMPLE 5

A standardized preparation of recombinant human TF with a
20 cofactor activity of 241 units/ml (specific activity of 3906 units/milligram) was serially diluted to create stock assay standards in the range of 8 to 0.25 units/ml. One hundred microliters of each stock standard was combined with 50 microliters of 120nM factor VIIa. Subsequently 50 microliters
25 of 150 μ M D-FPR-(n-butyl)ANSN was added and the rate of substrate hydrolysis was measured in a fluorometer at an excitation wavelength of 350 nm and an emission wavelength of 470 nm. A standard curve was generated in FIG.3 by plotting the change in fluorescent intensity over time versus the
30 concentration of TF (in units/ml). In a similar manner, a sample of TF (0.8 mg/ml) with an unknown amount of cofactor activity was assayed for comparison to the standard. After correcting for assay dilution, the unknown sample returned an assay value of 2803 units per milliliter, and thus a specific
35 activity of 3504 units per milligram. Consequently, this

allows for comparison of different preparations of TF using their specific activity, which is a direct indication of quality and functionality.

Example 6

- 5 Varying concentrations of fVIIa (0-200pM) were incubated with
40nM nM TF, in a buffer of 20 mM Hepes (N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 0.05 M Sodium
Chloride (NaCl), pH 8.0 (HBS), containing 0.1% (w/v)
polyethyleneglycol (PEG) and 25% (v/v) ethylene glycol for 10
10 minutes at room temperature, followed by the addition of 80 μ M
D-FPR-(cyclohexyl)ANSN. Substrate hydrolysis was allowed to
proceed for 24 hours at room temperature after which an
endpoint reading was taken in a fluorometer at an excitation
wavelength of 350 nm and an emission wavelength of 470 nm.
15 When a calibration curve was constructed by plotting the
relative fluorescence intensity versus factor VIIa
concentration, a linear relationship was observed with the
lower limit of detection being approximately 2 pM. In this
case, the optimized buffer conditions (pH, ionic strength, and
20 additives) along with an extended assay period and end-point
reading yielded a lower limit of detection that was 20 fold
lower than that observed using the standard assay conditions
outlined in "example 1".

Example 7

- 25 A microtiter assay plate was precoated with purified
recombinant tissue factor and residual plate binding sites were
blocked with bovine serum albumin using conventional coating
and blocking methods. Serial dilutions of factor VIIa in TBS,
pH 7.4 (20 nM to 8.5 pM) were added to the plate and allowed to
30 incubate for 2 hours at room temperature. The plate was then
washed with TBS, pH 7.4 to remove non-bound factor VIIa and
this was followed by the addition of 80 μ M D-FPR-
(cyclohexyl)ANSN. Substrate hydrolysis was allowed to proceed
for 24 hours at room temperature after which an endpoint
35 reading was taken in a fluorometer at an excitation wavelength

of 350 nm and an emission wavelength of 470 nm. When a calibration curve was constructed by plotting the relative fluorescence intensity versus factor VIIa concentration, a linear relationship was observed with the lower limit of
5 detection being approximately 8.5 pM.

The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it
10 pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the invention as set forth in the claims. To particularly point out and
15 distinctly claim the subject matter regarded as invention, the following claims conclude this specification.


What is claimed is:

1. A method for determining tissue factor (TF) activity in a sample suspected to contain TF, comprising:

- 5 (a) combining TF and a molar excess of factor VIIa (fVIIa) to produce a TF/fVIIa enzyme complex; and
 (b) detecting enzymatic activity of the complex using a fluorogenic or chromogenic substrate.

10

2. The method of claim 1, wherein the substrate is a compound of the formula:



or a pharmaceutically acceptable non-toxic salts thereof;

15 wherein

R₁ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms optionally substituted with C₁-C₆ alkoxy, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, cycloalkylalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula

20

25




R₅ represents hydrogen or an amino acid side chain;
 and

30

R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or a peptide residue;

5 R_2 is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula



10

R_5 represents hydrogen or an amino acid side chain; and

R_4 is hydroxy, C_1 - C_6 alkoxy, an amino acid or peptide residue; or

15

NR_1R_2 forms a nitrogen heterocycle; and

R_3 is an amino acid or a peptide residue.

20

3. The method of claim 1, where the substrate is a chromogenic substrate.

4. The method of claim 3, where the chromogenic substrate is a para-Nitroaniline-based substrate.

25

5. The method of claim 1, further comprising (c) generating a numerical value associated with the enzymatic activity of the sample and (d) comparing the numerical value with a standard curve of TF-dependent enzymatic activity.

30

6. The method of claim 5, wherein the standard curve is generated by quantifying TF-dependent enzymatic activity of the TF/fVIIa complex in samples with known concentrations of TF.

7. The method of claim 6, wherein the TF is native human tissue factor.

8. The method of claim 6, wherein TF source is brain tissue, placenta, endothelial cells, tissue extract, plasma, cell extract, synthetic or naturally derived thromboplastin, or
5 recombinant human tissue factor.

9. The method of claim 6, wherein the fVIIa is native human factor VIIa or recombinant factor VIIa.

10 10. The method of claim 6, wherein the TF and the fVIIa are not of human origin.

11. The method of claim 6, wherein the concentration of TF is from 0.1 pM to 1mM.
15

12. The method of claim 6, wherein the reaction mixture contains divalent metal ion or a metal ion chelator.

13. The method of claim 12, wherein the divalent metal
20 ion is calcium ion, magnesium ion or manganese ion.


14. The method of claim 12, wherein the metal ion chelator is ethylenediaminetetraacetic acid (EDTA) or ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
25 (EGTA).

15. A method for determining factor VIIa (fVIIa) enzymatic activity in a sample suspected to contain fVIIa, comprising:

- 30 (a) combining fVIIa and a molar excess of TF to produce a TF/fVIIa enzyme complex; and
(b) detecting the enzymatic activity of the complex using a fluorogenic substrate or a chromogenic substrate.

35

16. The method of claim 15, wherein the substrate is a compound of the formula:



or a pharmaceutically acceptable non-toxic salts thereof;
5 wherein

R₁ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms optionally substituted with C₁-C₆ alkoxy, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, cycloalkylalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula



R₅ represents hydrogen or an amino acid side chain;
and

20 R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or a peptide residue;

R₂ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the
30 formula



R₅ represents hydrogen or an amino acid side chain;
and

R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or peptide
residue; or

5 NR₁R₂ forms a nitrogen heterocycle; and

R₃ is an amino acid or a peptide residue.

17. The method of claim 15, where the substrate is a
chromogenic substrate.

10

18. The method of claim 17, where the chromogenic
substrate is a pNA-based substrate.

19. The method of claim 15, further comprising (c)
15 generating a numerical value associated with the enzymatic
activity of the sample and (d) comparing the numerical value
with a standard curve.

20. The method of claim 19, where the curve is generated
20 by quantifying fVIIa-dependent enzymatic activity of the
TF/fVIIa complex in samples with known concentrations of fVIIa.

21. The method of claim 19, wherein the fVIIa is native
human factor VIIa or recombinant human factor VIIa.

25

22. The method of claim 19, wherein the fVIIa source is
plasma, tissue extract, cell extract or recombinant material.

23. The method of claim 19, wherein the TF is native
30 human tissue factor or recombinant human tissue factor.

24. The method of claim 19, wherein the TF source is a
synthetic or naturally derived thromboplastin.

25. The method of claim 19, wherein the fVIIa and the TF
are not of human origin.

26. The method of claim 19, wherein the concentration of fVIIa is from 0.1 pM to 1mM.

5 27. The method of claim 19, wherein the reaction mixture contains divalent metal ion or a metal ion chelator.

28. The method of claim 27, wherein the divalent metal ion is calcium ion, manganese ion or magnesium ion.

10

29. The method of claim 27, wherein the metal ion chelator is ethylenediaminetetraacetic acid (EDTA) or ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA).




FIG. 1**FIG. 2**

Fig. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/35608

A. CLASSIFICATION OF SUBJECT MATTERIPC(7) : C12Q 1/56
US CL : 435/13, 4; 544 67

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
U.S. : 435/13, 4; 544/67

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,287,794 B1 (SAFAR et al) 11 September 2001 (11.09.2001), see entire document.	1-29
Y	US 5,399,487 A (BUTENAS et al) 21 March 1995 (21.03.1995), see entire document.	1-29

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier application or patent published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 08 March 2004 (08.03.2004)	Date of mailing of the international search report 27 MAY 2004
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer L Blaine Lankford <i>L. Lankford</i> Telephone No. 571-272-1600